natgillin/translations-raw huggingface dataset:
Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by week 12 compared to 30% of placebo maintenance patients.
Među bolesnicima koji u 4. tjednu nisu imali klinički odgovor, 43% bolesnika koji su primali dozu održavanja lijeka Humira imalo je klinički odgovor do 12. tjedna u odnosu na 30% u skupini bolesnika koji su uzimali placebo kao terapiju održavanja.
Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent at the time of the first visit (2 weeks) and were maintained through 6 months of therapy.
Među bolesnicima s ankilozantnim spondilitisom koji su primali Enbrel klinički odgovor bio je očit u trenutku prvog kontrolnog pregleda (nakon 2 tjedna), a zadržan je i tijekom trajanja terapije od 6 mjeseci.
Among patients with diarrhoea, the median time to first event was 2 days (range, 1 to 594 days) and the median duration of any grade of diarrhoea was 2 days (range, 1 to 910 days).
Među bolesnicima s proljevom medijan vremena do prvog događaja bio je 2 dana (raspon 1 do 594 dana), a medijan trajanja proljeva bilo kojeg stupnja bio je 2 dana (raspon 1 do 910 dana).
Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.
Među bolesnicima s plak psorijazom koji su primali Enbrel zabilježen je značajan odgovor u usporedbi s placebom već za vrijeme prve vizite (nakon 2 tjedna) koji se održao do kraja 24. tjedna terapije.
Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.
Klinički odgovor u bolesnika s psorijatičnim artritisom koji su primali Enbrel zamijećen je u vrijeme prve kontrole (4 tjedna) i održan je tijekom svih 6 mjeseci liječenja.
Among patients with reports of adverse reactions of elevations in either ALT or AST (all grades), the median time of onset observed in the study was 28 days with a range of onset 6 to 841 days for ALT and 1 to 680 days for AST.
Među bolesnicima s prijavljenim nuspojavama porasta ALT-a ili AST-a (svih stupnjeva), medijan vremena do početka koji je opažen u ispitivanju bio je 28 dana, s rasponom do početka od 6 do 841 dana za ALT i od 1 do 680 dana za AST.
Among patients with thrombocytopenia AEs, the median time to first event was 28 days (range, 1 to 968 days) and median duration per event was 14 days (range, 1 to 666 days).
Među bolesnicima s nuspojavama u obliku trombocitopenije, medijan vremena do prvog događaja bio je 28 dana (raspon 1 do 968 dana), a medijan trajanja po događaju bio je 14 dana (raspon 1 do 666 dana).
Among patients with worsening disease that had come back or failed to respond to at least one other treatment, around 70% responded to treatment with the Velcade-dexamethasone combination.
U bolesnika s pogoršanjem bolesti koja se vratila ili koji nisu odgovorili na najmanje jednu terapiju, pri čemu je 70% bolesnika odgovorilo na liječenje kombinacijom lijekova Velcade i deksametazona.
Among persistent-positive subjects in the Phase III studies, 1/10 (10%), 2/27 (7%) and 1/4 (25%) subjects in the placebo, 1 mg/kg and 10 mg/kg groups, respectively, experienced infusion reactions on a dosing day; these infusion reactions were all non-serious and mild to moderate in severity.
Među trajno pozitivnim ispitanicima u studijama Faze III, 1/10 (10%) ispitanika u placebo skupini, 2/27 (7%) ispitanika u skupini koja je primala dozu od 1 mg/kg, te 1/4 (25%) ispitanika koji su primali dozu od 10 mg/kg, imalo je infuzijske reakcije na dan primjene lijeka; nijedna od tih infuzijskih reakcija nije bila ozbiljna i bile su blage do umjerene težine.
Among prior relapsers in the T12/PR24 treatment group who had undetectable HCV RNA
Bolesnici s prethodno djelomičnim odgovorom
Among samples of oral mucosa, only 1 sample had detectable talimogene laherparepvec DNA during the study, but the sample did not test positive for presence of infective virus.
Među uzorcima oralne sluznice, u samo 1 uzorku tijekom ispitivanja nađene su detektabilne razine DNK virusa talimogene laherparepvec, ali uzorak nije bio pozitivan na prisutnost infektivnog virusa.
Among subjects with a genotypic sensitivity score of ≤ 1, 76% and 69% had HIV-1 RNA
Ispitanici s rezultatom genotipske osjetljivosti ≤ 1, 76% i 69% ispitanika imalo je HIV-1 RNK
Among the 1,618 dasatinib-treated patients with chronic phase CML, adverse reactions leading to discontinuation were reported in 329 (20.3%) patients, and among the 1,094 dasatinib-treated patients with advanced phase disease, adverse reactions leading to discontinuation were reported in 191 (17.5%) patients.
Među 1618 bolesnika s KML u kroničnoj fazi liječenih dasatinibom nuspojave koje su dovele do prekida liječenja prijavljene su u 329 (20,3%) bolesnika, dok su među 1094 bolesnika s bolešću u uznapredovaloj fazi liječena dasatinibom nuspojave koje su dovele do prekida liječenja prijavljene u 191 (17,5%) bolesnika.
Among the 11 subjects, 2 developed the emtricitabine-associated resistance substitution M184V.
Među tih 11 ispitanika, u njih 2 se razvila supstitucija M184V povezana s rezistencijom na emtricitabin.
Among the 122 subjects with measurable lymph nodes at both baseline and post-baseline, 67 subjects (54.9%) achieved a ≥ 50% decrease from baseline in the sum of the products of the diameters (SPD) of index lesions.
Od 122 ispitanika s mjerljivim limfnim čvorovima na prvom i kasnijim pregledima, 67 ispitanika (54,9%) doseglo je smanjenje zbroja umnožaka najvećih promjera (SPD) praćenih lezija ≥ 50%.
Among the 1226 randomised patients, 89.4% and 90.2% of patients treated with the placebo/FOLFIRI and ZALTRAP/FOLFIRI regimens, respectively, received prior oxaliplatin-based combination chemotherapy in the metastatic/advanced setting.
Od 1226 randomiziranih bolesnika, njih 89,4% koji su primali protokol placebo/FOLFIRI i 90,2% liječenih protokolom ZALTRAP/FOLFIRI prethodno je primalo kombiniranu kemoterapiju na bazi oksaliplatina za metastatsku/uznapredovalu bolest.
Among the 15,447 children in the catch-up vaccinated cohorts, there were no culture-confirmed IPD cases in the Synflorix groups while 5 vaccine serotype IPD cases were observed in the control groups (serotypes 4, 6B, 7F, 14 and 19F).
U 15 447 djece u cijepljenim kohortama nakon naknadne provedbe propuštene ili odgođene uobičajene imunizacije, nije bilo kulturom potvrđenih slučajeva IPB-a u Synflorix grupi dok je u kontrolnim grupama zabilježeno 5 IPB slučajeva izazvanih serotipovima zastupljenim u cjepivu (serotipovi 4, 6B, 7F, 14 i 19F).
Among the 21 patients, 3 developed the emtricitabine-associated resistance substitution M184V.
21 pacijenta, 3 je razvilo rezistentnu supstituciju M184V povezanu s emtricitabinom.
Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older.
Od 300 bolesnika (221 bolesnik u fazi III ispitivanja i 79 bolesnika u fazi II ispitivanja) liječenih s docetakselom u kombinaciji sa cisplatinom i 5-fluoruracilom u studiji koja je uključivala bolesnike s karcinomom želuca, njih 74 je bilo u odbi od 65 godina ili starijih, a 4 ih je bilo u dobi od 75 godina ili starijih.
Among the 314 subjects, 230 were infected with genotype 1a HCV and 84 were infected with genotype 1b HCV.
Od 314 ispitanika, njih 230 bilo je zaraženo HCV genotipom 1a, a njih 84 HCV genotipom 1b.
Among the 3189 patients treated with MabThera, 1135 (36%) experienced at least one IRR with 733/3189 (23%) of patients experiencing an IRR following first infusion of the first exposure to MabThera.
Od 3189 bolesnika liječenih lijekom MabThera, njih je 1135 (36%) imalo barem jednu reakciju povezanu s infuzijom, a 733/3189 (23%) bolesnika imalo je reakciju povezanu s infuzijom nakon prve infuzije pri prvom izlaganju lijeku MabThera.
Among the 37 surgeries that occurred during the study, of which 12 were major, in only one case the blood loss was more than expected.
Od 37 kirurških zahvata obavljenih tijekom ispitivanja, od kojih je 12 bilo velikih, samo u jednom slučaju gubitak krvi bio je veći od očekivanog.
Among the 54% of patients (247/456) who were receiving concomitant corticosteroids at the start of PURSUIT-Maintenance, the proportion of patients who maintained clinical response through week 54 and were not receiving concomitant corticosteroids at week 54 was greater in the 50 mg group (38%, 30/78) and 100 mg group (30%, 25/82) compared with the placebo group (21%, 18/87).
Od 54% bolesnika (247/456) koji su na početku ispitivanja PURSUIT-Maintenance istodobno primali kortikosteroide, održan klinički odgovor do 54. tjedna bez istodobne primjene kortikosteroida u tjednu zabilježen je u većeg udjela bolesnika koji su primali lijek u dozi od 50 mg (38%, 30/78) i 100 mg (30%, 25/82) u odnosu na bolesnike koji su primali placebo (21%, 18/87).
Among the 681 patients with diarrhoea, 104 patients (15%) were managed with treatment interruption and of these 98 (94%) were rechallenged with bosutinib.
Među 681 bolesnikom s proljevom, 104 bolesnika (15%) bilo je zbrinuto prekidom liječenja, a od toga je 98 (94%) ponovno izloženo bosutinibu.
Among the 75 subjects who received at least one dose of SOC, the total median exposure to SOC was 51 weeks and ranged from 0.4 to 52 weeks.
Od 75 ispitanika koja su primila najmanje jednu dozu liječenja u sklopu standardne skrbi, ukupni medijan izloženosti standardnoj skrbi bio je 51 tjedan, u rasponu od 0,4 do 52 tjedna.
Among the children who tested positive for antibodies to golimumab, 39% (25/69) had neutralising antibodies.
Među djecom koja su bila pozitivna na protutijela na golimumab, njih 39% (25/69) imalo je neutralizirajuća protutijela.
Among the HBeAg positive subjects randomised to tenofovir disoproxil fumarate, 16 of 65 subjects (25%) experienced HBeAg loss, and 8 of 65 subjects (12%) experienced anti-HBe seroconversion through week 240.
Među HBeAg-pozitivnih ispitanika randomiziranih za tenofovirdizoproksilfumarat, 16 od 65 (25%) ispitanika imalo je nestanak HBeAg, a 8 od 65 (12%) ispitanika imalo je anti-HBe serokonverziju kroz 240 tjedana.
Among the most frequent adverse reactions (at least in 2% of patients) in clinical studies in liver transplant patients receiving Envarsus were tremor, headache, fatigue, hyperkalaemia, hypertension, renal failure, blood creatinine increased, dizziness, hepatitis C, muscle spasms, tinea infection, leukopenia, sinusitis , and URTI, all of which are known to occur in the respective patient population under immunosuppressive treatment.
Među najčešćim nuspojavama (u najmanje 2% bolesnika) u kliničkim ispitivanjima bolesnika s presađenom jetrom koji primaju Envarsus bili su tremor, glavobolja, umor, hiperkalijemija, hipertenzija, zatajenje bubrega, povišeni kreatinin u krvi, omaglica, hepatitis C, spazam mišića, dermatofitije, leukopenija, sinusitis i infekcije gornjeg dišnog sustava, sve poznato da se sve pojavljuje u ovoj populaciji bolesnika koji primaju imunosupresivno liječenje.
Among the overall study population enrolled, the mean age was 33 years, 55% were female, 84% were Caucasian, 7% were Black, 7% were Hispanic, and 2% were of other ethnic origin.
U ukupnoj obuhvaćenoj ispitivanoj populaciji srednja dob bila je 33 godine, 55% bile su žene, 84% bijelci, 7% osobe crne rase, 7% hispanoamerikanci i 2% populacije bila je drugog etničkog podrijetla.
Among the patients treated with nivolumab in combination with ipilimumab in CA209067, 151/313 (48%) had the first onset of Grade 3 or 4 adverse reactions during the initial combination phase.
Među bolesnicima liječenima nivolumabom u kombinaciji s ipilimumabom u ispitivanju CA209067, u njih 151/313 (48%) prva nuspojava 3. ili 4. stupnja nastupila je tijekom početne faze kombinirane terapije.
Among the patients who entered the open-label 12 month period, 59% (125/213) of patients receiving continuous abatacept plus methotrexate treatment and 48% (92/192) of patients who initially received methotrexate and switched to combination with abatacept had no progression.
Među bolesnicima koji su ušli u otvoreno 12-mjesečno razdoblje ispitivanja, progresija nije nastupila u 59% (125/213) onih koji su kontinuirano liječeni abataceptom i metotreksatom te u 48% (92/192) bolesnika koji u najprije primali metotreksat i placebo pa su potom prebačeni na kombinaciju s abataceptom.
Among the patients who took Tarceva, the average survival was 8.6 months in those whose tumours were ‘EGFR IHC-positive’ (had EGFRs on their surface), and 5.0 months in those whose tumours were EGFR IHC-negative.
Među bolesnicima koji su uzimali lijek Tarceva, prosječna stopa preživljavanja bila je 8,6 mjeseci u bolesnika s tumorima koji su bili „EGFR IHC-pozitivni” (koji su imali EGFR-ove na površini tumora) i 5,0 mjeseci u bolesnika s tumorima koji su bili „EGFR IHC-negativni”.
Among the variants, 91% of V36M, 98% of T54A, 71% of T54S, 78% of V55A, 76% of R155K, 92% of A156S, 96% of I/V170A, 77% of R155K+T54S and
Od svih varijanti, sekvenciranjem populacije nije otkriveno 91% V36M, 98% T54A, 71% T54S, 78% V55A, 76
Among them, sequence data from paired baseline and on treatment HBV isolates were available for 2 of 4 patients.
Za 2 od ta 4 pacijenta bili su dostupni sekvencijski podaci iz sparenih početnih rezultata te HBV izolata tijekom liječenja.
Among them, the incidence of adrenal phaeochromocytomas was increased relative to control in males at all dose levels ( 3 mg/kg/day) and in females receiving 10 mg/kg/day and above.
Među njima je incidencija adrenalnog feokromocitoma u odnosu na kontrolne životinje bila povećana u mužjaka pri svim razinama doze ( 3 mg/kg na dan), a u ženki pri dozi od 10 mg/kg na dan ili višoj.
Among them, two patients experienced a clinically meaningful decline in estimated GFR which improved after discontinuation of tenofovir disoproxil fumarate.
Među njima su dva pacijenta imala klinički značajan pad procijenjenog GFR-a koji se poboljšao nakon prekida primjene tenofovirdizoproksilfumarata.
Among these 10 HIV-1 isolates, the mutations that emerged were M184V/I (n = 9) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase.
Među tih 10 HIV-1 izolata, mutacije koje su se pojavile bile su M184V/I (n = 9) i K65R/N (n = 2) u RT i T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), i N155H (n = 2) u integrazi.
Among these 37 deaths, the number (%) of deaths was 5/55 (9.1%), 10/74 (13.5%), and 22/100 (22%) in the sildenafil low, medium, and high dose groups, respectively.
Od tih 37 smrtnih slučajeva, broj (%) smrtnih slučajeva bio je 5/55 (9,1%), u skupini s niskom 10/74 (13,5%) u skupini sa srednjom 22/100 (22%) u skupini s visokom dozom sildenafila.
Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
U ta se stanja ubrajaju nefropatija povezana s BK virusom i progresivna multifokalna leukoencefalopatija (PML) povezana s JC virusom.
Among these conditions are BK virus-associated nephropathy and JC virus-associated progressive multifocal leukoencephalopathy (PML).
Navedena stanja uključuju nefropatiju povezanu s BK virusom i progresivnu multifokalnu leukoencefalopatiju (PML) povezanu s JC virusom.
Among these failures six patients treated with Cubicin and one patient treated with vancomycin were infected with Staphylococcus aureus that developed increasing MICs of daptomycin on or following therapy (see “Mechanisms of resistance” above).
Od tih neuspjelih slučajeva, šest bolesnika liječenih Cubicinom i jedan bolesnik liječen vankomicinom imali su infekcije izazvane Staphylococcus aureus kod kojih se tijekom ili nakon terapije povećao MIK za daptomicin (vidjeti “Mehanizmi rezistencije” iznad).
Among these patients, 28% receiving vedolizumab every eight weeks, 27% receiving vedolizumab every four weeks, and 13% receiving placebo achieved clinical remission at Week 52.
Od ovih bolesnika, 28% onih koji su primali vedolizumab svakih osam tjedana, 27% onih koji su primali vedolizumab svaka četiri tjedna, te 13% onih koji su primali placebo postiglo je kliničku remisiju u 52. tjednu.
Among these patients, 37% receiving vedolizumab every eight weeks, 35% receiving vedolizumab every four weeks, and 5% receiving placebo achieved clinical remission at Week 52.
Od tih bolesnika, 37% onih koji su primali vedolizumab svakih osam tjedana, 35% onih koji su primali vedolizumab svaka četiri tjedna, te 5% onih koji su primali placebo postiglo je kliničku remisiju u 52. tjednu.
Among these patients, the median time to first event was 28 days (range, 1 to 658 days) and the median duration per event was 12 days (range, 1 to 502 days).
Među tim bolesnicima, medijan vremena do prvog događaja bio je 28 dana (raspon 1 do 658 dana), a medijan trajanja po događaju bio je 12 dana (raspon,1 do 502 dana).
Among these patients, the OS benefit with Lonsurf was maintained (hazard ratio: 0.69, 95% CI [0.45 to 1.05]).
U toj skupini bolesnika, dobrobit u smislu OS uz primjenu Lonsurfa je bila održana (omjer hazarda 0,69; 95% CI [0,45 do 1,05]).
Among these patients, the OS benefit with Lonsurf was maintained (hazard ratio: 0.75, 95% CI [0.59 to 0.94]).
U toj skupini bolesnika, dobrobit u smislu OS uz primjenu Lonsurfa je bila održana (omjer hazarda 0,75; 95% CI [0,59 do 0,94]).
Among these, 1,585 women were treated with CE 0.45 mg/bazedoxifene 20 mg and 1,241 received placebo.
Među njima, 1585 žena dobivalo je 0,45 mg konjugiranih estrogena i 20 mg bazedoksifena, a 1241 žena dobivala je placebo.
Among these, two cases of platelets < 50 x 109/l were reported and attributed to the leukapheresis procedure.
Među njima su i dva slučaja s tromobocitima <50 x 109/l, što je pripisano postupku leukafereze.
among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
lijekove iz skupine tienopiridina (kao što su tiklopidin, prasugrel) (vidjeti dio 4.4)
among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*
što su tiklopidin, prasugrel) (vidjeti dio 4.4)
Among those 56 patients, 25 (44.6%) also showed the presence of neutralizing antibodies.
Od tih 56 bolesnika, u njih 25 (44,6%) pokazala se i prisutnost neutralizirajućih protutijela.
Among those patients treated with the ZALTRAP/FOLFIRI regimen developing grade 3-4 hypertension, 54% had onset during the first two cycles of treatment (see section 4.4).
Među bolesnicima liječenima protokolom ZALTRAP/FOLFIRI u kojih se razvila hipertenzija stupnja 3-4, u njih 54% je ona nastupila tijekom prva dva ciklusa liječenja (vidjeti dio 4.4).
Amongst 1,166 patients treated with lenvatinib, there were 4 cases (0.3%) of arterial thromboembolisms (2 cases of myocardial infarction and 2 cases of cerebrovascular accident) with a fatal outcome.
Među 1166 bolesnika liječenih lenvatinibom bila su 4 slučaja (0,3%) arterijske tromboembolije (2 slučaja infarkta miokarda i 2 slučaja cerebrovaskularnog inzulta) sa smrtnim ishodom.
Amongst 1,166 patients treated with lenvatinib, there were 4 cases (0.3%) of PRES (0.3% were Grade 3 or 4), all of which resolved after treatment and/or dose interruption, or permanent discontinuation.
Među 1166 bolesnika liječenih lenvatinibom bila su 4 slučaja (0,3%) PRES-a (0,3% bila su 3. ili stupnja), a svi su se povukli nakon liječenja i/ili privremenog prekida primjene doze ili trajnog prestanka primjene lijeka.
Amongst 1,166 patients treated with lenvatinib, there were 4 cases (0.3%) of PRES (0.3% were Grade 3 or 4), all of which resolved after treatment and/or dose interruption, or permanent discontinuation.
Među 1166 bolesnika liječenih lenvatinibom, bila su 4 slučaja (0,3%) PRES-a (0,3% bila su 3. ili 4. stupnja), a svi su se povukli nakon liječenja i/ili privremenog prekida doze ili trajnog prestanka primjene lijeka.
Amongst the 47 patients with an isolated Del (5q) cytogenetic abnormality and treated with lenalidomide 10 mg, 27 patients (57.4%) achieved red blood cell transfusion independence.
Među 47 bolesnika s izoliranom citogenetskom abnormalnosti koja se očituje kao delecija 5q, liječenih lenalidomidom u dozi od 10 mg, 27 bolesnika (57,4%) doseglo je neovisnost o transfuzijama crvenih krvnih stanica.
Amongst the most common adverse reactions reported for Aptivus were gastrointestinal complaints such as diarrhoea and nausea as well as hyperlipidaemia.
Među najčešćim nuspojavama prijavljenima uz Aptivus su gastrointestinalne tegobe kao što su proljev i mučnina, te hiperlipidemija.
Amongst the most serious and/or common adverse reactions reported in Herceptin usage (intravenous and subcutaneous formulations) to date are cardiac dysfunction, administration-related reactions, haematotoxicity (in particular neutropenia), infections and pulmonary adverse reactions.
Među najozbiljnije i/ili najčešće nuspojave dosad prijavljene pri primjeni lijeka Herceptin (u intravenskoj i supkutanoj formulaciji) ubrajaju se disfunkcija srca, reakcije povezane s primjenom lijeka, hematotoksičnost (osobito neutropenija), infekcije i plućne nuspojave.
Amongst those who responded (Pediatric ACR 30) at Week 24 (n=27 out of 30 patients), the Pediatric ACR 30 responses were maintained for up to 60 weeks in the OLE phase in patients who received Humira throughout this time period.
Među onima koji su odgovorili na terapiju (pedijatrijski odgovor ACR 30) u 24. tjednu (n=27 od 30 bolesnika), pedijatrijski odgovori ACR 30 održali su se do 60 tjedana u otvorenom produžetku ispitivanja u bolesnika koji su primali lijek Humira kroz ovo vremensko razdoblje.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study.
Među bolesnicima koji su imali klinički odgovor u 16. tjednu (n=144), pedijatrijski odgovori ACR 30/50/70/90 održali su se i do šest godina u otvorenom produžetku ispitivanja u bolesnika koji su uzimali lijek Humira tijekom cijeloga ispitivanja.
Amorphous aluminium hydroxyphosphate sulphate is included in the vaccine as an adjuvant.
Amorfni aluminijev hidroksifosfat sulfat uključen je u cjepivo kao adjuvans.
Amount Econor 10% oral powder (mg) required = Dose required (mg/kg) x pig bodyweight (kg) x 10 / daily feed intake (kg).
Potrebna količina Econor 10 % oralnog praška (mg) = potrebna doza (mg/kg) x tjelesna masa svinje (kg) x 10/dnevni unos hrane (kg)
Amount of Benlysta
Količina lijeka Benlysta
Amount of Ebilfumin suspension
Količina Ebilfumin suspenzije
Amount of PegIntron to administer (g)
Količina lijeka PegIntron koju treba primijeniti (µg)
amount of product per day (ml/day)
Količina proizvoda po danu (ml/dan)
Amount of Tamiflu suspension
Količina Tamiflu mješavine
Amount of ViraferonPeg to administer (µg)
Količina lijeka ViraferonPe koju treba primijeniti (µg)
Amount of ViraferonPeg to administer (µg)
Količina lijeka ViraferonPeg koju treba primijeniti (µg)
Amount of ViraferonPeg to administer (g)
Količina lijeka ViraferonPeg koju treba primijeniti (µg)
Amount per 1 ml dose (sheep)
Količina po dozi od 1 ml (ovce)
Amount Set to Inject
Količina podešena za ubrizgavanje
Amount(s) to be administered and administration route
Količine koje se primjenjuju i način primjene
Amounts to be administered and administration route
Doziranje i način primjene
Amounts to be administered and administration route
Doziranje i put primjene
Amounts to be administered and administration route
Količine koje se primjenjuju i put primjene
Amounts to be administered and administration route
Količine koje se primjenjuju i putprimjene
Amounts to be administered and administration route
Način primjene i doze
Amounts to be administered and administration route Cattle:
Količine koje se primjenjuju i način primjene Goveda:
Amounts to be administered and administration route Cattle:
Količine koje se primjenjuju i put primjene Goveda:
Amounts to be administered and administration route Dogs:
Količine koje se primjenjuju i način primjene Psi:
Amounts to be administered and administration route Dogs:
Količine koje se primjenjuju i put primjene Psi: